Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib with PRRT in Metastatic Neuroendocrine Tumors
NCT05053854Phase 1Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2021
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in Neuroendocrine Neoplasm (NEN), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Maximum Tolerated Dose at 18 months and Dose Limiting Toxicity at 6 weeks. Started Dec 2021; status: recruiting.
02
Drugs
talazoparib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05053854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053854.